Mirimus

Executive Summary

Mirimus is a New York-based biotechnology company founded in 2010 by a team of renowned scientists from Cold Spring Harbor Laboratory. The company focuses on advancing medical research through innovative diagnostics, therapeutics, and the development of animal and cell models for disease study. By leveraging cutting-edge genetic and genomic technologies, Mirimus aims to address critical human health issues on a global scale. Despite being in the pre-clinical stage with no disclosed funding or valuation, the company's strong scientific foundation and award-winning track record position it as a potential player in the genomics space. However, limited public information on specific pipeline programs or commercial progress suggests an early-stage, high-risk profile.

Upcoming Catalysts (preview)

• Q4 2026Strategic Partnership or Licensing Deal35% success
• H1 2027Major Funding Round (Series A or B)40% success
• Q2 2026Publication of Key Preclinical Data50% success